NVCR News and Press, NovoCure Limited From 02/25/21

NovoCure Limited. (NVCR) Q4 2020 Results Earnings Conference Call February 25, 2021, 08:00 AM ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medica...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q4 earnings call. For further details see: NovoCure Limited 2020 Q4 - Results - Earnings Call Presentation

NovoCure (NVCR): Q4 GAAP EPS of $0.04 misses by $0.09.Revenue of $143.95M (+45.1% Y/Y) beats by $0.46M.There were 3,411 active patients, representing 17% growth Y/Y.The Co. expects growth in R&D to continue into 2021 as they work to advance the pipeline programs and increase acceptance of...

Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020 Quarterly net income of $4.9 million with $0.05 in earnings per share Novocure (NASDAQ: NVCR) today reported fin...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is $0.13 and the consensus Revenue Estimate is $143.49M (+44.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten...

Delcath Systems develops drug/device combos to treat liver cancers. The company’s stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data. Delcath updated the trial design for its lead product to address past issues around pa...

Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’...

Cancer has typically been treated by either radiation, surgery, drugs. But Novocure (NASDAQ: NVCR) has developed a fourth paradigm, tumor treating fields, which can inhibit the growth of tumors by inhibiting tumor cell division. In this video from Motley Fool Live, recorded...

Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy. The secret to the stellar gains is the Optune system - a novel system to help treat various forms of cancer via ele...

NovoCure (NVCR) sees Q4 revenue of $144.0 (+45% Y/Y) vs. a consensus $133.62M.Full year 2020 net revenues of $494.4M (+41% Y/Y).Asaf Danziger, Novocure’s CEO. “Through our clinical and product development efforts, we believe we are just beginning to unlock the potential of ...